Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Apremilast

FDA-approved product (tablet, oral), marketed as Apremilast, Otezla, Otezla Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Apremilast
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Behcet's syndrome
  • Immune system disease
  • Oral ulcer
  • Psoriasis
  • Psoriasis vulgaris
  • Psoriatic arthritis
  • Pustulosis palmaris et plantaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective immunosuppressants
FDA pharmacologic class
Phosphodiesterase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Apremilast in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Apremilast with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    NCT07352566 · start 2026-08-01

    Registered record
    Registry ID
    NCT07352566
    Conditions
    Psoriasis; Atopic Dermatitis
    Interventions
    In situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene; Tapinarof; Crisaborole; Tacrolimus; Adalimumab; Etanercept; Certolizumab; Infliximab; Secukinumab; Ixekizumab; Apremilast; Risankizumab; Ustekinumab; Hydroxychloroquine; Methotrexate; Mycophenolate; Azathioprine; Chloroquine; Cyclosporine; Tofacitinib; Deucravacitinib; Dupilumab; Tralokinumab; Guselkumab; Tildrakizumab; Baractinib; Abrocitinib; Upadacitinib; Lebrikizumab; Nemolizumab; Ruxolitinib; Bimekizumab; Roflumilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis
    InterventionIn situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene +32 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL.

    NCT07543640 · start 2026-04-01

    Registered record
    Registry ID
    NCT07543640
    Conditions
    Flexural Psoriasis (Also Known as Inverse or Intertriginous Psoriasis) and Genital Psoriasis
    Interventions
    Methotrexate; Roflumilast 500 Mcg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2026-08
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFlexural Psoriasis (Also Known as Inverse or Intertriginous Psoriasis) and Genital Psoriasis
    InterventionMethotrexate; Roflumilast 500 Mcg Oral Tablet
    PhasePhase 2
    Registry statusNot yet recruiting

  • Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)

    NCT07234838 · start 2026-02-01

    Registered record
    Registry ID
    NCT07234838
    Conditions
    Psoriasis; Condyloma Acuminata; Biotherapies
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2028-08-01
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Condyloma Acuminata; Biotherapies
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis

    NCT07190391 · start 2025-09-30

    Registered record
    Registry ID
    NCT07190391
    Conditions
    Psoriasis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-09-30
    Completion
    2027-10-31
    Enrolment
    425

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Ustekinumab in BEhçet's Syndrome STudy

    NCT07244614 · start 2025-09-01

    Registered record
    Registry ID
    NCT07244614
    Conditions
    Behçet's Syndrome (BS)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2029-12-31
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBehçet's Syndrome (BS)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients

    NCT06863493 · start 2025-06-01

    Registered record
    Registry ID
    NCT06863493
    Conditions
    Psoriasis (PsO)
    Interventions
    SFA002; Otezla; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-06-01
    Completion
    2026-09-01
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis (PsO)
    InterventionSFA002; Otezla; Placebo
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • HPP737 in Adult Patients With Plaque Psoriasis

    NCT07712731 · start 2025-04-18

    Registered record
    Registry ID
    NCT07712731
    Conditions
    Psoriasis
    Interventions
    HPP737; Placebo matching HPP737; Apremilast; Placebo matching Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2025-04-18
    Completion
    2026-04-01
    Enrolment
    607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionHPP737; Placebo matching HPP737; Apremilast; Placebo matching Apremilast
    PhasePhase 3
    Registry statusCompleted

  • Apremilast for Alcohol Use Disorder Treatment in Women and Men

    NCT06324435 · start 2024-05-08

    Registered record
    Registry ID
    NCT06324435
    Conditions
    Alcohol Use Disorder
    Interventions
    Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2024-05-08
    Completion
    2026-08-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionApremilast
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

    NCT06088043 · start 2023-11-06

    Registered record
    Registry ID
    NCT06088043
    Conditions
    Plaque Psoriasis
    Interventions
    TAK-279; Placebo; Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-11-06
    Completion
    2025-10-22
    Enrolment
    693

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionTAK-279; Placebo; Apremilast
    PhasePhase 3
    Registry statusCompleted

  • A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

    NCT06108544 · start 2023-11-06

    Registered record
    Registry ID
    NCT06108544
    Conditions
    Plaque Psoriasis
    Interventions
    TAK-279; Placebo; Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-11-06
    Completion
    2025-11-07
    Enrolment
    1,108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionTAK-279; Placebo; Apremilast
    PhasePhase 3
    Registry statusCompleted

  • A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

    NCT06088199 · start 2023-10-24

    Registered record
    Registry ID
    NCT06088199
    Conditions
    Plaque Psoriasis
    Interventions
    Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-10-24
    Completion
    2026-08-12
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionApremilast
    PhasePhase 3
    Registry statusCompleted

  • [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET

    NCT05703685 · start 2023-06-22

    Registered record
    Registry ID
    NCT05703685
    Conditions
    Depression
    Interventions
    Lung scan; Apremilast; 18F-PF-06445974
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-06-22
    Completion
    2029-04-11
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionLung scan; Apremilast; 18F-PF-06445974
    PhasePhase 1
    Registry statusRecruiting

  • A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

    NCT05565560 · start 2023-01-25

    Registered record
    Registry ID
    NCT05565560
    Conditions
    Plaque Psoriasis
    Interventions
    Apremilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-01-25
    Completion
    2026-09-03
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionApremilast
    PhasePhase 3
    Registry statusActive not recruiting

  • Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis

    NCT04227314 · start 2022-04-10

    Registered record
    Registry ID
    NCT04227314
    Conditions
    Recurrent Aphtous Stomatitis
    Interventions
    Apremilast; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-04-10
    Completion
    2026-12
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Aphtous Stomatitis
    InterventionApremilast; Placebo oral tablet
    PhasePhase 3
    Registry statusRecruiting

  • Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

    NCT04804553 · start 2022-03-17

    Registered record
    Registry ID
    NCT04804553
    Conditions
    Active Juvenile Psoriatic Arthritis
    Interventions
    Apremilast; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-03-17
    Completion
    2028-12-29
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActive Juvenile Psoriatic Arthritis
    InterventionApremilast; Placebo
    PhasePhase 3
    Registry statusRecruiting